Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Cash Flows From Operating Activities | ||||
| Net Income | -41,693 | -26,651 | -5,431 | 0 |
| Depreciation Amortization | 3 | N/A | N/A | 0 |
| Accounts payable and accrued liabilities | 5,403 | 1,237 | N/A | N/A |
| Other Working Capital | 6,438 | 2,456 | 912 | 0 |
| Other Operating Activity | 18,968 | 18,793 | 2,820 | 0 |
| Operating Cash Flow | $-10,881 | $-4,165 | $-1,699 | $0 |
| Cash Flows From Investing Activities | ||||
| PPE Investments | -31 | N/A | N/A | 0 |
| Purchase Sale Intangibles | -3,000 | -3,000 | N/A | N/A |
| Other Investing Activity | -3,000 | -3,000 | 0 | 0 |
| Investing Cash Flow | $-3,031 | $-3,000 | $N/A | $0 |
| Cash Flows From Financing Activities | ||||
| Debt Issued | 1,673 | 1,673 | 1,673 | N/A |
| Debt Repayment | -1,673 | -1,645 | -1,646 | N/A |
| Common Stock Issued | 167,162 | N/A | N/A | N/A |
| Other Financing Activity | 125,384 | 18,337 | 18,000 | 0 |
| Financing Cash Flow | $292,546 | $18,365 | $18,027 | $0 |
| End Cash Position | 278,634 | 11,200 | 16,328 | 0 |
| Net Cash Flow | $278,634 | $11,200 | $16,328 | $0 |
| Free Cash Flow | ||||
| Operating Cash Flow | -10,881 | -4,165 | -1,699 | 0 |
| Capital Expenditure | -31 | N/A | N/A | N/A |
| Free Cash Flow | -10,912 | -4,165 | -1,699 | 0 |